Vol 7, No 4 (2021)
Review paper
Published online: 2022-03-29

open access

Page views 4956
Article views/downloads 215
Get Citation

Connect on Social Media

Connect on Social Media

COVID-19 vaccination in patients with rheumatic diseases — status February 2022

Violetta Opoka-Winiarska1, Elżbieta Smolewska2
Rheumatol. Forum 2021;7(4):155-164.

Abstract

Vaccination is the most effective strategy to prevent and reduce the effects of the COVID-19 pandemic. The purpose of this article is to summarize the current data and recommendations regarding vaccination against COVID-19 in children and adults with rheumatic diseases in Poland and worldwide. This paper also shows reports on vaccination in adults and children with rheumatic diseases, including efficacy, safety and adverse effects. Furthermore, ACR and PRES recommendations for COVID 19 vaccination in adults and children with rheumatic diseases were presented, including special situations that cause difficulties in daily clinical practice.

Article available in PDF format

View PDF Download PDF file

References

  1. Tavares AC, de Melo AK, Cruz VA, et al. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Adv Rheumatol. 2022; 62(1): 3.
  2. Antonelli A, Fallahi P, Elia G, et al. Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases. Lancet Rheumatol. 2021; 3(10): e675–e676.
  3. Michelena X, Borrell H, López-Corbeto M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020; 50: 564–570.
  4. Calvo C, Udaondo C. Rheumatic Diseases EPICO-AEP Working Group. COVID-19 in Children With Rheumatic Diseases in the Spanish National Cohort EPICO-AEP. J Rheumatol. 2021; 48(7): 1190–1192.
  5. Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel). 2020; 7(7).
  6. García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, et al. Spanish Pediatric Intensive Care Society working group on SARS-CoV-2 infection. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020; 24(1): 666.
  7. Swann OV, Holden KA, Turtle L, et al. ISARIC4C Investigators. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020; 370: m3249.
  8. https://covid19.who.int/ (274.02.2022).
  9. https://www.gov.pl/web/szczepimysie/raport-szczepien-przeciwko-covid-19 (27.02.2022).
  10. https://stat.gov.pl/obszary-tematyczne/ludnosc/ (27.02.2022).
  11. European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised.(27.02.2022). (27.02.2022).
  12. Charakterystyka produktu leczniczego Comirnaty. https://szczepienia.pzh.gov.pl/dla-lekarzy/lista-szczepionek-oraz-chpl-do-pobrania-2/ (27.02.2022).
  13. Charakterystyka produktu leczniczego Spikevax. https://szczepienia.pzh.gov.pl/dla-lekarzy/lista-szczepionek-oraz-chpl-do-pobrania-2/ (27.02.2022).
  14. Charakterystyka produktu leczniczego COVID-19 VaccineJanssen. https://szczepienia.pzh.gov.pl/dla-lekarzy/lista-szczepionek-oraz-chpl-do-pobrania-2/ (27.02.2022).
  15. Charakterystyka produktu leczniczego Vaxzevria. https://szczepienia.pzh.gov.pl/dla-lekarzy/lista-szczepionek-oraz-chpl-do-pobrania-2/ (27.02.2022).
  16. Charakterystyka produktu leczniczego Nuvaxoid. https://szczepienia.pzh.gov.pl/dla-lekarzy/lista-szczepionek-oraz-chpl-do-pobrania-2/ (???).
  17. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results (27.02.2022).
  18. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html (27.02.2022).
  19. Flanagan KL, MacIntyre CR, McIntyre PB, et al. SARS-CoV-2 Vaccines: Where Are We Now? J Allergy Clin Immunol Pract. 2021; 9(10): 3535–3543.
  20. Haslak F, Gunalp A, Cebi MN, et al. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study. Int J Rheum Dis. 2022 [Epub ahead of print].
  21. Frenck RW, Klein NP, Kitchin N, et al. C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3): 239–250.
  22. Kashif A, Berman G, Honghong Z. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. 2021; 385: 2241–2251.
  23. Woodworth KR, Moulia D, Collins JP, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(45): 1579–1583.
  24. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15): 1412–1423.
  25. Machado PM, Lawson-Tovey S, Hyrich K, et al. LB0002 COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE. Annals of the Rheumatic Diseases. 2021; 80(Suppl 1): 199–200.
  26. Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80(10): 1317–1321.
  27. Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(5152): 1755–1760.
  28. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html (15.11.2021).
  29. Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021; 326(14): 1390–1399.
  30. Blumenthal KG, Phadke NA, Bates DW. Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink. JAMA. 2021; 326(14): 1375–1377.
  31. Simone A, Herald J, Chen A, et al. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med. 2021; 181(12): 1668–1670.
  32. Diaz GA, Parsons GT, Gering SK, et al. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021; 326(12): 1210–1212.
  33. PRES update regarding COVID-19 vaccination in children with rheumatic diseases. https://www.pres.eu/clinical-affairs/guidelines.html (27.02.2022).
  34. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf. (27.02.2022).
  35. https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf (27.02.2022).